BIIB

Biogen's stock price has been impacted by several events over the past six months. The company reported Q4 2025 earnings with adjusted EPS exceeding estimates and issued aggressive guidance for 2026. Biogen announced plans to acquire Apellis and entered into an agreement with TJ Biopharma. The FDA approved a new high-dose regimen of SPINRAZA® for Spinal Muscular Atrophy, and the FDA extended the review period for LEQEMBI IQLIK. Biogen reported its Q1 2026 results, with revenues exceeding analysts' expectations. Analysts have shown constructive sentiment, lifting Biogen's fair value estimate and price targets.